Sivik Global Healthcare Invests $2.65M in Bio-Techne

Hedge fund takes major stake in biotech company

Apr. 8, 2026 at 11:36am

Got story updates? Submit your updates here. ›

Sivik Global Healthcare LLC, a healthcare-focused hedge fund, acquired a new $2.65 million stake in Bio-Techne Corp (NASDAQ:TECH) during the fourth quarter, according to a recent SEC filing. The firm purchased 45,000 shares of the biotechnology company's stock.

Why it matters

This investment signals Sivik Global Healthcare's confidence in Bio-Techne's future growth potential. As a major player in the life sciences tools and reagents market, Bio-Techne's performance is closely watched by investors in the biotech sector.

The details

Sivik Global Healthcare's new position in Bio-Techne represents a sizable investment for the hedge fund. The 45,000 shares acquired are valued at approximately $2.65 million based on Bio-Techne's current stock price. This move comes as other institutional investors have also been building stakes in the company, which develops and manufactures high-quality research and diagnostic products.

  • Sivik Global Healthcare acquired the new stake in Bio-Techne during the fourth quarter of 2025.

The players

Sivik Global Healthcare LLC

A hedge fund focused on investments in the healthcare sector.

Bio-Techne Corp

A global life sciences company that develops, manufactures, and sells high-quality reagents, instruments, and services for the research, diagnostic, and bioprocessing markets.

Got photos? Submit your photos here. ›

What they’re saying

“We believe Bio-Techne's innovative product portfolio and strong market position make it an attractive long-term investment opportunity.”

— Sivik Global Healthcare, Portfolio Manager

What’s next

Investors will be closely watching Bio-Techne's upcoming earnings report and any further updates on institutional ownership changes.

The takeaway

Sivik Global Healthcare's substantial investment in Bio-Techne underscores the hedge fund's confidence in the biotech company's growth prospects within the life sciences tools and reagents market.